MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today the publication of a clinical communication in Blood (the journal of the American Society of Hematology) demonstrating clinical activity of the company’s lead compound, Ceflatonin® (Homoharringtonine, HHT1) against Gleevec® (imatinib mesylate)-resistant, accelerated phase chronic myeloid leukemia (CML) associated with the T315I BCR-ABL kinase domain mutation.
